$ cat ./records/partnered-with-who-on-tuberculosis-drug-research-to-counter-drug--2003.txt
Partnered with WHO on tuberculosis drug research to counter drug-resistant strains
[RECORD.TXT] · cat --full
The Gates Foundation partnered with the World Health Organization on a tuberculosis drug research program to accelerate development of new treatments for drug-resistant TB strains. The collaboration targeted multidrug-resistant tuberculosis (MDR-TB), which was spreading across Eastern Europe, Central Asia, and sub-Saharan Africa while resisting existing antibiotic regimens. The partnership helped re-establish TB drug discovery as a viable research field after decades of pharmaceutical industry disinvestment from diseases concentrated in low-income populations.
Source: https://www.who.int/teams/global-tuberculosis-programme
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Cascade Investment Begins Quietly Acquiring US Farmland Through Washington State and the Pacific Northwest
Next →
Funded major initiative into small high schools to improve U.S. graduation rates
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.